AR034331A1 - Una molecula de conjugado inmunogenico, metodo para su preparacion, composicion farmaceutica y vacuna que lo comprenden, anticuerpo purificado y equipo de inmunoensayo de diagnostico que lo incluye - Google Patents

Una molecula de conjugado inmunogenico, metodo para su preparacion, composicion farmaceutica y vacuna que lo comprenden, anticuerpo purificado y equipo de inmunoensayo de diagnostico que lo incluye

Info

Publication number
AR034331A1
AR034331A1 ARP020101723A ARP020101723A AR034331A1 AR 034331 A1 AR034331 A1 AR 034331A1 AR P020101723 A ARP020101723 A AR P020101723A AR P020101723 A ARP020101723 A AR P020101723A AR 034331 A1 AR034331 A1 AR 034331A1
Authority
AR
Argentina
Prior art keywords
vaccine
preparation
pharmaceutical composition
immunogenic conjugate
purified antibody
Prior art date
Application number
ARP020101723A
Other languages
English (en)
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR034331A1 publication Critical patent/AR034331A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Una molécula de conjugado inmunogénico que comprende ácido hialurónico enlazado covalentemente con un portador de polipéptido inmunológicamente apropiado útil para proveer la protección inmunogénica tanto activa como pasiva para aquellos infectado con o en riesgo de infección con el grupo A y el grupo C de estreptococos. Composición farmacéutica que lo comprende junto con un portador farmacéuticamente aceptable, vacuna que lo incluye y método para su preparación. Anticuerpo purificado que se une a la molécula de dicho conjugado inmunogénico y equipo de inmunoensayo de diagnóstico para detectar una infección mediante estreptococos que lo incluye.
ARP020101723A 2001-05-11 2002-05-10 Una molecula de conjugado inmunogenico, metodo para su preparacion, composicion farmaceutica y vacuna que lo comprenden, anticuerpo purificado y equipo de inmunoensayo de diagnostico que lo incluye AR034331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/853,367 US20020192205A1 (en) 2001-05-11 2001-05-11 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci

Publications (1)

Publication Number Publication Date
AR034331A1 true AR034331A1 (es) 2004-02-18

Family

ID=25315838

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101723A AR034331A1 (es) 2001-05-11 2002-05-10 Una molecula de conjugado inmunogenico, metodo para su preparacion, composicion farmaceutica y vacuna que lo comprenden, anticuerpo purificado y equipo de inmunoensayo de diagnostico que lo incluye

Country Status (15)

Country Link
US (1) US20020192205A1 (es)
EP (1) EP1385554A2 (es)
JP (1) JP2005508854A (es)
KR (1) KR20030096369A (es)
CN (1) CN1525869A (es)
AR (1) AR034331A1 (es)
BR (1) BR0209562A (es)
CA (1) CA2446555A1 (es)
CO (1) CO5550467A2 (es)
EC (1) ECSP034888A (es)
HU (1) HUP0400840A3 (es)
MX (1) MXPA03010283A (es)
PL (1) PL366692A1 (es)
SK (1) SK15122003A3 (es)
WO (1) WO2002092131A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物
US20070225484A1 (en) * 2006-03-25 2007-09-27 Framroze Bomi P Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
CA2773755C (en) * 2008-09-09 2017-04-25 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
CN102264444B (zh) * 2008-10-27 2015-08-05 诺华股份有限公司 纯化方法
CN102010469B (zh) * 2010-10-22 2013-02-27 上海贝西生物科技有限公司 一种抗透明质酸单克隆抗体及其用途
CN104302670A (zh) * 2012-02-07 2015-01-21 Phi生物医药股份有限公司 制造用于经皮给药的透明质酸-蛋白结合体的方法以及由该方法制造的用于经皮给药的透明质酸-蛋白结合体
CN104237500B (zh) * 2014-09-30 2016-09-28 博奥赛斯（天津）生物科技有限公司 一种透明质酸固相包被方法
EP3600442A1 (en) 2017-03-22 2020-02-05 Genentech, Inc. Optimized antibody compositions for treatment of ocular disorders
IT201900022626A1 (it) * 2019-12-02 2021-06-02 Ub Care S R L Metodo per la determinazione del contenuto di sodio ialuronato in un idrogel
CN115590774B (zh) * 2022-10-20 2024-05-03 珠海原妙医学科技股份有限公司 透明质酸脂质体组装体及其制备方法和应用
CN119158011A (zh) * 2024-05-30 2024-12-20 江苏坤力生物制药有限责任公司 一种增强重组蛋白抗原免疫原性的方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
JPH0912600A (ja) * 1995-06-22 1997-01-14 Shiseido Co Ltd ヒアルロン酸ナトリウムに対するモノクローナル抗体及びその製造方法
CA2297072A1 (en) * 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
CA2332455C (en) * 1998-06-01 2012-08-14 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Also Published As

Publication number Publication date
BR0209562A (pt) 2004-03-30
WO2002092131A2 (en) 2002-11-21
US20020192205A1 (en) 2002-12-19
JP2005508854A (ja) 2005-04-07
HUP0400840A2 (hu) 2004-07-28
KR20030096369A (ko) 2003-12-24
CO5550467A2 (es) 2005-08-31
CA2446555A1 (en) 2002-11-21
HUP0400840A3 (en) 2004-10-28
CN1525869A (zh) 2004-09-01
SK15122003A3 (sk) 2004-10-05
WO2002092131A3 (en) 2003-03-20
EP1385554A2 (en) 2004-02-04
PL366692A1 (en) 2005-02-07
ECSP034888A (es) 2004-05-28
MXPA03010283A (es) 2004-12-06

Similar Documents

Publication Publication Date Title
Yuan et al. Zwitterionic peptide cloak mimics protein surfaces for protein protection
Mizel et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates
CA2271249C (en) Macromolecular neuraminidase-binding compounds
BR112021012225A8 (pt) Agrupamento biologicamente ativo de moléculas
BR0210598A (pt) Complexo solúvel que compreende uma glicoproteìna retroviral de superfìcie
ES2164883T3 (es) Compuestos y metodos para la diagnosis de la leishmaniasis.
BRPI9911389B8 (pt) peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo
CY1108597T1 (el) Συνθεσεις που περιεχουν παραγοντα συνδεσης υποδοχεα οχ-40 ή νουκλεϊνικο οξυ που κωδικοποιει αυτον και μεθοδοι για αυξηση της αντιγονου-ειδικης ανοσοαποκρισης
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
CA2251464A1 (en) Non-dendritic backbone peptide carrier
BR9814473A (pt) Imunógenos anti-retrovirais, preparação e uso
DE69518978D1 (de) Gruppe a streptokokkenpolysaccharide immunogen-zusammensetzungen und verfahren
WO2019032480A1 (en) PROTEINS F PRE-FUSION OF RSV STABILIZED IN TERMS OF CONFORMATION
WO2004050711A3 (en) Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
WO2002092131A3 (en) Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins
KR20240031857A (ko) Covid-19 백신을 임베딩하기 위한 파상풍 백신 플랫폼
BR9106159A (pt) Polipeptideo sintetico,vacina,estojo para detectar hiv ou anticorpos contra hiv,molecula de dna,composicao farmaceutica,anticorpo ou fragmento de ligacao de antigeno do mesmo,processos de terapia ou profilaxia de infeccao hiv,de detectar hiv,de diagnosticar infeccao hiv e para a manufatura de um polipeptideo sintetico,de uma composicao farmaceutica e de um anticorpo ou fragmento de ligacao do mesmo
Agodoa et al. Precipitating antigen-antibody systems are required for the formation of subepithelial electron-dense immune deposits in rat glomeruli.
DK0491865T3 (da) Konjugatvaccine for gruppe B-Streptococcus
CA2332642A1 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
EE200100366A (et) Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks
RU2010129856A (ru) Новая вакцина для лечения связанных с микобактерией нарушений
ATE82687T1 (de) Gegen pseudomonas aeruginosa infektionen wirksame praeparationen und verfahren zu ihrer herstellung.
ATE221786T1 (de) Synthetischer impfstoff zum schutz gegen infektionen mit dem menschlichen immunschwächevirus
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FA Abandonment or withdrawal